Author | David P. Steensma, MD | OncLive

Author | David P. Steensma, MD

Articles

Dr. Steensma on the Utility of Venetoclax in MDS

March 26, 2020

Video

David P. Steensma, MD, discusses the potential utility of venetoclax in myelodysplastic syndrome.

Dr. David Steensma on Myelodysplastic Syndrome

April 11, 2016

Video

David P. Steensma, MD, Senior Physician, Associate Professor of Medicine, Harvard Medical School, Dana Farber Cancer Institute discusses myelodysplastic syndromes.

Dr. Steensma on Midostaurin for Patients With AML

December 06, 2015

Video

David P. Steensma, MD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses a phase III study comparing midostaurin with placebo in combination with daunorubicin cytarabine induction, high-dose cytarabine consolidation, and as maintenance therapy in newly diagnosed patients with acute myeloid leukemia (AML) with FLT3 mutations.

Dr. Steensma on ODAC's Pertuzumab Decision

September 12, 2013

Video

David P. Steensma, MD, from the Dana-Farber Cancer Institute, provides insight into the ODAC decision to recommend approval for a neoadjuvant pertuzumab-containing regimen for patients with HER2-positive breast cancer.

x